• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Ingevity Corporation

    5/7/25 4:15:57 PM ET
    $NGVT
    Major Chemicals
    Industrials
    Get the next $NGVT alert in real time by email
    S-8 POS 1 forms-8pos.htm S-8 POS

     

    As filed with the Securities and Exchange Commission on May 7, 2025

    Registration No. 333-211430

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    POST-EFFECTIVE AMENDMENT NO. 1

    TO

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    INGEVITY CORPORATION

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   47-4027764

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

     

    4920 O’Hear Avenue, Suite 400

    North Charleston, South Carolina 29405

    (843) 740-2300

    (Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

     

    Ingevity Corporation 2025 Omnibus Incentive Plan

    Ingevity Corporation 2016 Omnibus Incentive Plan

    (Full title of the plan)

     

     

     

    Ryan C. Fisher

    Senior Vice President, General Counsel, and Corporate Secretary

    Ingevity Corporation

    4920 O’Hear Avenue, Suite 400

    North Charleston, South Carolina 29405

    (843) 740-2300

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

     

    Large accelerated filer ☒ Accelerated filer ☐
           
    Non-accelerated filer ☐ Smaller reporting company ☐
           
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    Explanatory Note

     

    Ingevity Corporation (the “Registrant” or “Company”) filed a Registration Statement on Form S-8 (File No. 333-211430) with the Securities and Exchange Commission (the “Commission”) on May 18, 2016 (the “Original Registration Statement”) registering 4,000,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), issuable under the Ingevity Corporation 2016 Omnibus Incentive Plan (the “2016 Plan”).

     

    On April 30, 2025, the Company’s stockholders approved the Ingevity Corporation 2025 Omnibus Incentive Plan (the “2025 Plan”), and on such date (the “Effective Date”) the 2025 Plan became effective. Following the Effective Date, no further awards were authorized for grant under the 2016 Plan. The total number of shares of Common Stock authorized for issuance under the 2025 Plan includes, in addition to 425,000 new shares of Common Stock (registered on a new registration statement on Form S-8 filed contemporaneously with this Post-Effective Amendment), (a) shares of Common Stock that remain available under the 2016 Plan immediately prior to the Effective Date, and (b) shares of Common Stock underlying any equity awards previously granted under the 2016 Plan as of the Effective Date that, on or after the Effective Date, are forfeited, terminated, expire or lapse without being exercised, or any such awards that are settled for cash (collectively, the shares of Common Stock described in clauses (a) and (b) above, the “Rollover Shares”). On and after the Effective Date, the Rollover Shares may be issued under the 2025 Plan.

     

    The Company is filing this Post-Effective Amendment No. 1 to the Original Registration Statement (the “Post-Effective Amendment”) pursuant to Item 512(a)(1)(iii) of Regulation S-K to cover the offering of the Rollover Shares under the 2025 Plan. No additional shares of Common Stock are being registered hereby.

     

    1

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The documents containing the information required in Part I of this Registration Statement have been or will be sent or given to participating employees as specified in Rule 428(b)(1) under the Securities Act of 1933, as amended, or the Securities Act, in accordance with the rules and regulations of the Commission. Such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. These documents and the documents incorporated by reference into this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    2

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference

     

    The following documents filed by the Registrant with the Commission are incorporated herein by reference:

     

      (1)

    The Registrant’s Annual Report on Form 10-K filed with the Commission on February 19, 2025 (Commission File No. 001-37586);

         
      (2)

    The Registrant’s Quarterly Report on Form 10-Q filed with the Commission on May 6, 2025 (Commission File No. 001-37586);

         
      (3)

    The Registrant’s Current Reports on Form 8-K, excluding any information furnished under Items 2.02 or 7.01 thereof, filed with the Commission on March 10, 2025, March 31, 2025, May 1, 2025 and May 5, 2025 (Commission File No. 001-37586); and

         
      (4)

    The description of the Registrant’s securities contained in Exhibit 4.3 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 28, 2023 (Commission File No. 001-37586).

     

    All reports and other documents filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel

     

    Not applicable.

     

    II-1

     

     

    Item 6. Indemnification of Directors and Officers

     

    The Registrant is governed by the Delaware General Corporation Law, or DGCL. Section 145 of the DGCL provides that a corporation may indemnify any person, including an officer or director, who was or is, or is threatened to be made, a party to any threatened, pending or completed legal action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person was or is an officer, director, employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such officer, director, employee or agent acted in good faith and in a manner such person reasonably believed to be in, or not opposed to, the corporation’s best interest and, for criminal proceedings, had no reasonable cause to believe that such person’s conduct was unlawful. A Delaware corporation may indemnify any person, including an officer or director, who was or is, or is threatened to be made, a party to any threatened, pending or contemplated action or suit by or in the right of such corporation, under the same conditions, except that such indemnification is limited to expenses (including attorneys’ fees) actually and reasonably incurred by such person, and except that no indemnification is permitted without judicial approval if such person is adjudged to be liable to such corporation. Where an officer or director of a corporation is successful, on the merits or otherwise, in the defense of any action, suit or proceeding referred to above, or any claim, issue or matter therein, the corporation must indemnify that person against the expenses (including attorneys’ fees) which such officer or director actually and reasonably incurred in connection therewith. The Company’s amended and restated certificate of incorporation provides that, to the fullest extent permitted by the DGCL, no director or officer will be personally liable to the Company or to its shareholders for monetary damages for breach of fiduciary duty as a director or officer, as applicable. The provisions of the Company’s amended and restated certificate of incorporation apply to an officer of the Company only if he or she is a director of the Company and is acting in his or her capacity as director, and do not apply to officers of the Company who are not directors.

     

    The Company’s amended and restated bylaws require the Company to indemnify any person who was or is made a party or is threatened to be made a party to, or is otherwise involved in, a legal proceeding by reason of the fact that he or she is or was a director, officer or employee of Ingevity, or while a director, officer or employee of the Company, is or was serving at the Company’s request in a fiduciary capacity with another enterprise (including any corporation, partnership, joint venture, trust, or other enterprise, including service with respect to any employee benefit plans maintained or sponsored by the Company), to the fullest extent authorized by the DGCL, as it exists or may be amended, against all expense, liability or loss (including attorneys’ fees, judgments, fines, U.S. Employee Retirement Income Security Act of 1974, as amended, excise taxes or penalties and amounts paid in settlement by or on behalf of such person) reasonably incurred or suffered in connection with such service. The Company is authorized under its amended and restated bylaws to maintain directors’ and officers’ insurance protecting the Company, any director, officer or employee of ours, against any expense, liability or loss, whether or not the Company would have the power to indemnify the person under the DGCL. The Company may, from time to time, indemnify any of its agents to the fullest extent permitted with respect to directors, officers and employees in its amended and restated bylaws.

     

    The foregoing is only a general summary of certain aspects of Delaware law and the Company’s amended and restated certificate of incorporation and bylaws dealing with indemnification of directors, officers and employees of the Company.

     

    Item 7. Exemption from Registration Claimed

     

    Not applicable.

     

    II-2

     

     

    Item 8. Exhibits

     

    Exhibit No.   Description
         
    4.1   Ingevity Corporation Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q, as filed with the Commission on May 2, 2024).
         
    4.2   Ingevity Corporation Fourth Amended and Restated Bylaws, effective October 22, 2024 (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, as filed with the Commission on October 25, 2024).
         
    4.3   Indenture, dated as of October 28, 2020, among Ingevity Corporation, the guarantors party thereto and U.S. Bank National Association, as trustee, with respect to the 3.875% Senior Notes Due 2028 (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, as filed with the Commission on October 28, 2020).
         
    4.4   Ingevity Corporation 2025 Omnibus Incentive Plan (filed as Appendix B to the Registrant’s Proxy Statement on Schedule 14A for its 2025 Annual Meeting (File No. 001-37586), filed on March 20, 2025 and incorporated herein by reference)
         
    5.1*   Legal Opinion of Baker & Hostetler LLP.
         
    5.2   Legal Opinion of McGuireWoods LLP as to the legality of the securities being registered with respect to the 2016 Plan, filed as Exhibit 5.1 to the Company’s Registration Statement on Form S-8 (Registration No. 333-211430) filed on May 18, 2016 and incorporated herein by reference.
         
    23.1*   Consent of Independent Registered Public Accounting Firm.
         
    23.2*   Consent of Baker & Hostetler LLP (contained in Exhibit 5.1).
         
    24.1*   Power of Attorney (included in signature page to this Registration Statement).

     

    * Filed herewith.

     

    Item 9. Undertakings

     

      (a) The undersigned Registrant hereby undertakes:

     

      (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

      (i) to include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    II-3

     

     

      (ii) To reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” table in the effective registration statement; and

     

      (iii) To include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in this registration statement; provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if this registration statement is on Form S-8 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this registration statement.

     

      (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
         
      (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

      (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
         
      (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    II-4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to Form S-8 Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of North Charleston, State of South Carolina, on this 7th day of May, 2025.

     

    INGEVITY CORPORATION  
         
    By: /s/ Mary Dean Hall  
    Name: Mary Dean Hall  
    Title: Executive Vice President and Chief Financial Officer  

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Ryan C. Fisher and Mary Dean Hall, and each of them acting individually, as his or her attorney-in-fact, with full power of substitution, for him or her and in any and all capacities, to sign any and all amendments to this Registration Statement on this Form S-8 (including any post-effective amendments thereto) and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ David Li   President, Chief Executive Officer and Director   May 7, 2025
    David Li   (Principal Executive Officer)    
             
     /s/ Mary Dean Hall   Executive Vice President and Chief Financial Officer   May 7, 2025
    Mary Dean Hall   (Principal Financial Officer)    
             
    /s/ Phillip J. Platt   Senior Vice President, Finance and Chief Accounting Officer   May 7, 2025
    Phillip J. Platt   (Principal Accounting Officer)    
             
    /s/ Jean S. Blackwell   Director   May 7, 2025
    Jean S. Blackwell        
             
     /s/ Luis Fernandez-Moreno   Director   May 7, 2025
    Luis Fernandez-Moreno        
             
    /s/ Diane H. Gulyas    Director   May 7, 2025
    Diane H. Gulyas        
             
    /s/ Bruce D. Hoechner    Director   May 7, 2025
    Bruce D. Hoechner        
             
    /s/ Frederick J. Lynch    Director   May 7, 2025
    Frederick J. Lynch        
             
     /s/ Karen G. Narwold   Director   May 7, 2025
    Karen G. Narwold        
             
    /s/ Daniel F. Sansone    Director   May 7, 2025
    Daniel F. Sansone        
             
     /s/ F. David Segal   Director   May 7, 2025
    F. David Segal        
             
     /s/ J. Kevin Willis   Director   May 7, 2025
    J. Kevin Willis        
             
     /s/ Benjamin G. Wright   Director   May 7, 2025
    Benjamin G. Wright        

     

    II-5

     

    Get the next $NGVT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NGVT

    DatePrice TargetRatingAnalyst
    2/26/2025$62.00 → $65.00Market Perform → Outperform
    BMO Capital Markets
    8/7/2024$58.00Market Perform → Market Outperform
    CJS Securities
    4/22/2024$52.00 → $62.00Hold → Buy
    Jefferies
    11/6/2023$49.00Market Outperform → Market Perform
    CJS Securities
    10/3/2023$62.00 → $53.00Buy → Hold
    Loop Capital
    8/7/2023$71.00 → $60.00Outperform → Market Perform
    BMO Capital Markets
    7/27/2023$64.00 → $75.00Hold → Buy
    Loop Capital
    5/5/2023$92.00 → $64.00Buy → Hold
    Loop Capital
    More analyst ratings

    $NGVT
    Leadership Updates

    Live Leadership Updates

    See more
    • Ingevity Files Definitive Proxy Statement and Issues Letter to Stockholders

      Board and Management Team Have Taken Significant and Decisive Action to Respond to External Market Challenges Key Transformational Changes Are Driving Strong Financial Results and Stock Price Outperformance Continued Execution of Proven Strategy Positions Ingevity to Unlock Significant Additional Stockholder Value Company Urges Stockholders to Vote "FOR" ONLY Ingevity's Highly Qualified Director Nominees on the WHITE Proxy Card Launches VoteIngevity.com Providing Additional information for Stockholders Ingevity Corporation (NYSE:NGVT) today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with its 2025 Annual Meet

      3/20/25 5:34:00 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity announces appointment of David H. Li as president and CEO

      Li brings 25-year+ record of driving successful corporate transformation, long-term growth and stockholder value creation at premier global specialty materials supplier Ingevity Corporation (NYSE:NGVT) today announced that its board of directors has appointed David H. Li as the company's president and CEO, effective as of April 7, 2025, and that he is expected to join the board of directors following the 2025 Annual Meeting. Li succeeds Ingevity board member, Luis Fernandez-Moreno, who has been serving as interim president and CEO since October 2024. Fernandez-Moreno will remain on Ingevity's board. This press release features multimedia. View the full release here: https://www.businesswir

      3/10/25 4:15:00 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity Highlights Significant Momentum on Actions Underway to Drive Improved Performance and Value Creation

      Delivered Record Year in Performance Materials and Strategic Repositioning in Performance Chemicals Is Already Demonstrating Results Business Portfolio Review Is Progressing with Recently Announced Strategic Alternatives Process for Industrial Specialties Product Line and Evaluation of Additional Portfolio and Cost Reduction Actions Ongoing Provides Information About Engagement with Vision One Ingevity Corporation (NYSE:NGVT) today issued the following letter to stockholders in response to the presentation issued by Vision One Management Partners ("Vision One") earlier today: Dear Ingevity Stockholders, The Ingevity Board of Directors and leadership team are committed to taking ag

      2/25/25 4:21:00 PM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ingevity Corporation

      SC 13G/A - Ingevity Corp (0001653477) (Subject)

      11/12/24 3:54:24 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Ingevity Corporation

      SC 13G/A - Ingevity Corp (0001653477) (Subject)

      11/4/24 11:52:25 AM ET
      $NGVT
      Major Chemicals
      Industrials
    • SEC Form SC 13D/A filed by Ingevity Corporation (Amendment)

      SC 13D/A - Ingevity Corp (0001653477) (Subject)

      2/28/24 5:30:32 PM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ingevity reports first quarter 2025 financial results

      HIGHLIGHTS: Net sales of $284.0 million, down 17% compared to prior year, primarily due to repositioning actions in Performance Chemicals, which included the exit of certain lower-margin end markets Net income of $20.5 million and diluted earnings per share (EPS) of $0.56 reflects before-tax special charges of $20.2 million; adjusted earnings of $36.4 million and diluted adjusted EPS of $0.99 Adjusted EBITDA of $91.3 million increased 23% and adjusted EBITDA margin improved to 32.1% due primarily to the successful execution of repositioning actions in Performance Chemicals and continued strong profitability in Performance Materials Operating cash flow of $25.4 million with free cash

      5/5/25 4:15:00 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity announces dates for first-quarter 2025 earnings release and webcast

      Ingevity Corporation (NYSE:NGVT) announced today that it will release its first-quarter 2025 earnings after the stock market close on Monday, May 5, 2025. The company will host a live webcast on Tuesday, May 6, at 9:00 a.m. (Eastern) to discuss first-quarter 2025 fiscal results. The webcast can be accessed here or on the investors section of Ingevity's website. Participants may also listen to the conference call by dialing 833 470 1428 (inside the U.S.) and entering access code 815699. Callers outside the U.S. can find global dial-in numbers here. For those unable to join the live event, a recording will be available beginning at approximately 2:00 p.m. (Eastern) on May 6, 2025, through M

      4/24/25 9:00:00 AM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity Files Definitive Proxy Statement and Issues Letter to Stockholders

      Board and Management Team Have Taken Significant and Decisive Action to Respond to External Market Challenges Key Transformational Changes Are Driving Strong Financial Results and Stock Price Outperformance Continued Execution of Proven Strategy Positions Ingevity to Unlock Significant Additional Stockholder Value Company Urges Stockholders to Vote "FOR" ONLY Ingevity's Highly Qualified Director Nominees on the WHITE Proxy Card Launches VoteIngevity.com Providing Additional information for Stockholders Ingevity Corporation (NYSE:NGVT) today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with its 2025 Annual Meet

      3/20/25 5:34:00 PM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    Financials

    Live finance-specific insights

    See more
    • Ingevity reports first quarter 2025 financial results

      HIGHLIGHTS: Net sales of $284.0 million, down 17% compared to prior year, primarily due to repositioning actions in Performance Chemicals, which included the exit of certain lower-margin end markets Net income of $20.5 million and diluted earnings per share (EPS) of $0.56 reflects before-tax special charges of $20.2 million; adjusted earnings of $36.4 million and diluted adjusted EPS of $0.99 Adjusted EBITDA of $91.3 million increased 23% and adjusted EBITDA margin improved to 32.1% due primarily to the successful execution of repositioning actions in Performance Chemicals and continued strong profitability in Performance Materials Operating cash flow of $25.4 million with free cash

      5/5/25 4:15:00 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity announces dates for first-quarter 2025 earnings release and webcast

      Ingevity Corporation (NYSE:NGVT) announced today that it will release its first-quarter 2025 earnings after the stock market close on Monday, May 5, 2025. The company will host a live webcast on Tuesday, May 6, at 9:00 a.m. (Eastern) to discuss first-quarter 2025 fiscal results. The webcast can be accessed here or on the investors section of Ingevity's website. Participants may also listen to the conference call by dialing 833 470 1428 (inside the U.S.) and entering access code 815699. Callers outside the U.S. can find global dial-in numbers here. For those unable to join the live event, a recording will be available beginning at approximately 2:00 p.m. (Eastern) on May 6, 2025, through M

      4/24/25 9:00:00 AM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity reports fourth quarter and full year 2024 financial results

      Fourth Quarter: Net sales of $298.8 million decreased 20% compared to prior year primarily due to repositioning actions in the Performance Chemicals segment that resulted in the exit of lower-margin end markets Net income of $16.6 million and diluted earnings per share (EPS) of $0.46, including pre-tax restructuring charges of $23.4 million; adjusted earnings of $34.7 million and diluted adjusted EPS of $0.95 Adjusted EBITDA of $80.6 million and adjusted EBITDA margin of 27.0% Operating cash flow of $64.5 million and free cash flow of $39.6 million, which included the second and final $50.0 million installment of a termination fee for a long-term crude tall oil (CTO) supply agreemen

      2/18/25 4:15:00 PM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ingevity upgraded by BMO Capital Markets with a new price target

      BMO Capital Markets upgraded Ingevity from Market Perform to Outperform and set a new price target of $65.00 from $62.00 previously

      2/26/25 7:15:06 AM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity upgraded by CJS Securities with a new price target

      CJS Securities upgraded Ingevity from Market Perform to Market Outperform and set a new price target of $58.00

      8/7/24 9:18:13 AM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity upgraded by Jefferies with a new price target

      Jefferies upgraded Ingevity from Hold to Buy and set a new price target of $62.00 from $52.00 previously

      4/22/24 7:39:26 AM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    SEC Filings

    See more
    • SEC Form S-8 filed by Ingevity Corporation

      S-8 - Ingevity Corp (0001653477) (Filer)

      5/7/25 4:16:03 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • SEC Form S-8 POS filed by Ingevity Corporation

      S-8 POS - Ingevity Corp (0001653477) (Filer)

      5/7/25 4:15:57 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • SEC Form 10-Q filed by Ingevity Corporation

      10-Q - Ingevity Corp (0001653477) (Filer)

      5/6/25 4:24:35 PM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Blackwell Jean was granted 4,057 shares, increasing direct ownership by 145% to 6,857 units (SEC Form 4)

      4 - Ingevity Corp (0001653477) (Issuer)

      5/5/25 6:42:08 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Director Fernandez-Moreno Luis M was granted 4,057 shares, increasing direct ownership by 8% to 53,105 units (SEC Form 4)

      4 - Ingevity Corp (0001653477) (Issuer)

      5/5/25 6:38:06 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Director Lynch Frederick J was granted 4,057 shares, increasing direct ownership by 18% to 26,359 units (SEC Form 4)

      4 - Ingevity Corp (0001653477) (Issuer)

      5/5/25 6:33:42 PM ET
      $NGVT
      Major Chemicals
      Industrials